NASDAQ:NAGE Niagen Bioscience (NAGE) Stock Price, News & Analysis $11.51 -0.21 (-1.79%) As of 06/5/2025 04:00 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsHeadlinesSEC FilingsTrendsBuy This Stock About Niagen Bioscience Stock (NASDAQ:NAGE) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Niagen Bioscience alerts:Sign Up Key Stats Today's Range$11.45▼$11.8050-Day Range$5.42▼$11.7852-Week Range$2.31▼$12.07Volume632,420 shsAverage Volume846,974 shsMarket Capitalization$906.64 millionP/E Ratio67.71Dividend YieldN/APrice Target$13.00Consensus RatingBuy Company OverviewNiagen Bioscience, Inc. is a global bioscience company, which engages in acquiring, developing, and commercializing proprietary-based ingredient technologies. It is pioneering research on nicotinamide adenine dinucleotide (NAD+). The company’s patent portfolio includes Nicotinamide Riboside (NR) and other NAD+ precursors, which are commercialized as the flagship ingredient Niagen. It operates through the following segments: Consumer Products, Ingredients, and Analytical Reference Standards and Services. The Consumer Products segment provides finished dietary supplement products that contain the firm’s proprietary ingredients directly to consumers as well as to distributors. The Ingredients segment supplies ingredients as raw materials to the manufacturers of consumer products. The Analytical Reference Standards and Services segment includes supply of phytochemical reference standards and other research and development services. The company was founded by Mark S. Germain and Frank L. Jaksch, Jr. in 1999 and is headquartered in Los Angeles, CA.Read More… Niagen Bioscience Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks17th Percentile Overall ScoreNAGE MarketRank™: Niagen Bioscience scored higher than 17% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion2.5 / 5Analyst RatingBuy Consensus RatingNiagen Bioscience has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageNiagen Bioscience has only been the subject of 1 research reports in the past 90 days.Read more about Niagen Bioscience's stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Niagen Bioscience is 67.71, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 24.48.Price to Earnings Ratio vs. SectorThe P/E ratio of Niagen Bioscience is 67.71, which means that it is trading at a more expensive P/E ratio than the Manufacturing sector average P/E ratio of about 22.63. Short InterestN/AShort Interest LevelN/A Short InterestThere is no current short interest data available for NAGE. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldNiagen Bioscience does not currently pay a dividend.Dividend GrowthNiagen Bioscience does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Short InterestThere is no current short interest data available for NAGE. News and Social Media2.9 / 5News Sentiment0.30 News SentimentNiagen Bioscience has a news sentiment score of 0.30. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.88 average news sentiment score of Manufacturing companies.News Coverage This WeekMarketBeat has tracked 6 news articles for Niagen Bioscience this week, compared to 3 articles on an average week.Search Interest17 people have searched for NAGE on MarketBeat in the last 30 days. This is an increase of 55% compared to the previous 30 days.MarketBeat Follows7 people have added Niagen Bioscience to their MarketBeat watchlist in the last 30 days. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Niagen Bioscience insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 9.39% of the stock of Niagen Bioscience is held by insiders.Percentage Held by InstitutionsOnly 15.41% of the stock of Niagen Bioscience is held by institutions.Read more about Niagen Bioscience's insider trading history. Receive NAGE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Niagen Bioscience and its competitors with MarketBeat's FREE daily newsletter. Email Address NAGE Stock News HeadlinesNiagen Bioscience to Present at Oppenheimer’s 25th Annual Consumer Growth and E-Commerce ConferenceJune 4 at 12:58 PM | finance.yahoo.comNiagen Bioscience to Present at Oppenheimer's 25th Annual Consumer Growth and E-Commerce ConferenceJune 4 at 8:32 AM | businesswire.comEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal with Saudi Arabia to power its new AI empire 🤯 We’re talking about hundreds of thousands of chips, including their latest Grace Blackwell supercomputer.June 6, 2025 | Timothy Sykes (Ad)NAGE stock soars to 52-week high, hits $11.17 amid robust gainsJune 3 at 10:53 PM | investing.comCanaccord Genuity Group Begins Coverage on Niagen Bioscience (NASDAQ:NAGE)May 29, 2025 | americanbankingnews.comCanaccord Genuity Initiates Coverage of Niagen Bioscience (NAGE) with Buy RecommendationMay 28, 2025 | msn.comNAGE Niagen Bioscience, Inc.May 23, 2025 | seekingalpha.comNiagen Bioscience: Overbought After RallyMay 22, 2025 | seekingalpha.comSee More Headlines NAGE Stock Analysis - Frequently Asked Questions How have NAGE shares performed this year? Niagen Bioscience's stock was trading at $5.48 at the start of the year. Since then, NAGE stock has increased by 110.0% and is now trading at $11.51. View the best growth stocks for 2025 here. How do I buy shares of Niagen Bioscience? Shares of NAGE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorManufacturing Industry Medicinal Chemicals Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:NAGE Previous SymbolNASDAQ:NAGE CIK1386570 WebN/A Phone(310) 388-6706FaxN/AEmployees120Year FoundedN/APrice Target and Rating Average Stock Price Target$13.00 High Stock Price Target$13.00 Low Stock Price Target$13.00 Potential Upside/Downside+12.9%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E Ratio67.71 Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual Sales$107.93 million Price / Sales8.40 Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding Shares78,770,000Free FloatN/AMarket Cap$906.64 million OptionableN/A Beta1.94 20 High-Yield Dividend Stocks that Could Ruin Your RetirementAlmost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.Get This Free Report This page (NASDAQ:NAGE) was last updated on 6/6/2025 by MarketBeat.com Staff From Our PartnersEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredElon just did WHAT!?As you may recall, Biden and the Fed were working on a central bank digital currency, or CBDC. Had they got...Brownstone Research | SponsoredYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredHow to target 627% gains from Trump’s tweetsPresident Trump is shaking up the market with his tweets and Truth Social posts... But while this chaos has...Monument Traders Alliance | SponsoredDalio heeds Buffett’s warning… [$319 million stake in gold]Dalio bought a gold ETF… I don’t recommend that for the average retail investor. The real upside is in profita...Golden Portfolio | SponsoredTrump plotting new lockdown?It's listed inside the White House's own documents: Federal Register notice 90 FR 4544 to be exact. And wh...Porter & Company | SponsoredWhy hasn't Elon tweeted about this?Behind the scenes, there's an entirely different Tesla story brewing… . It's about a quiet stream of income...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Niagen Bioscience Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share Niagen Bioscience With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.